- Home
- CMMB vs BEEM Comparison
CMMB vs BEEM Comparison
Compare CMMB & BEEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- BEEM
- Stock Information
- Founded
- CMMB 2004
- BEEM 2006
- Country
- CMMB Israel
- BEEM United States
- Employees
- CMMB N/A
- BEEM N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- BEEM Semiconductors
- Sector
- CMMB Health Care
- BEEM Technology
- Exchange
- CMMB Nasdaq
- BEEM Nasdaq
- Market Cap
- CMMB 23.6M
- BEEM 22.3M
- IPO Year
- CMMB N/A
- BEEM N/A
- Fundamental
- Price
- CMMB $1.20
- BEEM $1.39
- Analyst Decision
- CMMB Strong Buy
- BEEM Strong Buy
- Analyst Count
- CMMB 2
- BEEM 4
- Target Price
- CMMB $9.00
- BEEM $9.00
- AVG Volume (30 Days)
- CMMB 167.2K
- BEEM 193.6K
- Earning Date
- CMMB 05-08-2025
- BEEM 04-11-2025
- Dividend Yield
- CMMB N/A
- BEEM N/A
- EPS Growth
- CMMB N/A
- BEEM N/A
- EPS
- CMMB N/A
- BEEM N/A
- Revenue
- CMMB N/A
- BEEM $49,336,000.00
- Revenue This Year
- CMMB N/A
- BEEM $27.41
- Revenue Next Year
- CMMB N/A
- BEEM $58.00
- P/E Ratio
- CMMB N/A
- BEEM N/A
- Revenue Growth
- CMMB N/A
- BEEM N/A
- 52 Week Low
- CMMB $0.58
- BEEM $1.33
- 52 Week High
- CMMB $2.55
- BEEM $7.68
- Technical
- Relative Strength Index (RSI)
- CMMB 50.27
- BEEM 30.42
- Support Level
- CMMB $1.08
- BEEM $1.33
- Resistance Level
- CMMB $1.25
- BEEM $1.48
- Average True Range (ATR)
- CMMB 0.11
- BEEM 0.19
- MACD
- CMMB 0.04
- BEEM -0.02
- Stochastic Oscillator
- CMMB 83.65
- BEEM 7.50
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
About BEEM Beam Global
Beam Global produces sustainable technology for electric vehicle (EV) charging, outdoor media, and energy security, without the construction, disruption, and costs of grid-tied solutions. Its products are founded upon its patented EV ARC and Solar Treelines and include BeamTrak patented solar tracking, and ARC Technology energy storage, along with EV charging, outdoor media, and disaster preparedness packages. From start to finish, the company develops, patents, designs, engineers, and manufactures renewably energized products that help the environment, empower communities, and keep people moving.